Theme: Fifty Shades of Metabolomics and Methodological Development

World Metabolomics 2016

World Metabolomics 2016

OMICS International welcomes you to attend the 5th International Conference and Exhibition on Metabolomics & Systems Biology during May 16-18, 2016 Osaka, Japan. The attending delegates include Editorial Board Members of related OMICS Group Journals. This is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. The main theme of the conference is “Fifty Shades of Metabolomics and Methodological Development”. OMICS International Organizes 300+ conferences, 500+ workshops and 200+ symposiums on Clinical, Medicine, Pharma and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

The global metabolomics market is expected to grow at a strong CAGR during the forecast period of 2014 to 2019 The global metabolomics market is expected to grow at a strong CAGR during the forecast period of 2014 to 2019 and is estimated to be worth $2,100 million by 2019. The market is mainly driven by the increasing research funding for metabolomics from governments and private investors, growing demand for personalized medicine in the U.S. and Europe, and the increasing need for toxicology testing. 

World Metabolomics 2016 invites all interested participants to join us for this esteemed event at the exquisite destination Osaka. For more: conference series.com 

Metabolomics and Cancer Therapeutic Approaches 

Cancer is a devastating disease that alters the metabolism of a cell and the surrounding milieu. Metabolomics in pharmaceutical research becoming an increasingly popular tool in the life sciences since it is a relatively fast and accurate technique that can be applied with either a particular focus or in a global manner to reveal new knowledge about biological systems.. NFCR has delivered more than $330 million in funding to cancer research leading to numerous breakthroughs, including prevention strategies, earlier diagnostic techniques, and new anticancer drugs and therapies. The Division of Cancer Biology (DCB) supports and facilitates basic research in all areas of cancer biology at academic institutions and research foundations across the United States and abroad.  As part of the National Cancer Institute, the Federal Government’s principal agency for cancer research and training, DCB provides funding for research that investigates the basic biology behind all occurrences of cancer. Current metabolomic methodologies  is being used to discover diagnostic cancer biomarkers in the clinic, to discover pathways involved in cancer that could be used for new targets and to monitor metabolic biomarkers during therapeutic intervention. Studying cancer through metabolomics could reveal metabolite platform for robust validation of biomarkers for cancer that could be useful for its future prognosis, diagnosis and therapy. There have been many novel approaches to cancer therapeutics  that have employed a range of different analytical platforms. When Cancer metabolism meets systems biology  network models may guide to cancer therapy. 

Metabolomics Applications in Diseases

Metabolomics is applied to investigate several human diseases, to improve their diagnosis and prevention, and to design better therapeutic strategies. Metabolomic profiling has been used to identify novel biomarkers and mechanisms of cardiovascular disease risk. Nutrition and Metabolism Center and Center for Human Genetics at Duke University where the research is going on with National Institutes of Health grants . Metabolomics can provide certain advantages relative to other “omics” technologies (genomics, transcriptomics, proteomics) in diabetes research. CEDAM (Centre for Endocrinology, Diabetes and Metabolism) research is committed to a bench-to-bedside approach, taking research through from basic science discovery to clinical application. This is facilitated by current MRC Experimental Medicine and Biomarker Grants and enhanced by the close proximity of lab facilities, Wellcome Trust Clinical Research Facility and the Queen Elizabeth Hospital (University Hospital NHS Foundation Trust) . Metabolomic approach provides novel insights into the mechanistic studies of antitumor drugs from a point distinct from traditional medicine investigations. Various new technologies have be employed for methodology development of metabolomics. Technical advances have spurred the application of metabolomics in a variety of diverse research areas spanning basic, biomedical, and clinical sciences. 

Metabolomics in Precision Medicine

Metabolomics, the post-genomic study of the molecules and processes that make up metabolism, appears as a potentially radical new way of examining biology and disease. Precision Medicine is an approach to discovering and developing medicines and vaccines that delivers superior outcomes for patients, by integrating clinical and molecular information to understand the biological basis of disease. Pharmacometabolomics informs and compliments pharmacogenomics and together they provide building blocks for Quantitative and Systems Pharmacology . Precision offers next generation solutions to maximize your success in translational research. The advent of massive parallel sequencing is responsible of a paradigm shift in biomarker discovery and clinical trial design on the way to what is now called "biomarker-driven cancer medicine" or "precision medicine." Complementing robust investments to broadly support research, development, and innovation, the President’s 2016 Budget will provide a $215 million investment for the National Institutes of Health (NIH), together with the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) to support this effort.

Frontiers of Metabolomics Research

Metabolomic studies can lead to enhanced understanding of disease mechanisms and to new diagnostic markers as well as enhanced understanding of mechanisms for drug or xenobiotic effect and increased ability to predict individual variation in drug response phenotypes. Howard University Center for Computational Biology and Bioinformatics (CCBB) is to encourage and promote the application of computational approaches to the study of biomedical and disease processes. New software and increasingly sophisticated NMR metabolite spectral databases are advancing the unique abilities of NMR spectroscopy to identify and quantify small molecules in solution for studies of metabolite biomarkers and metabolic flux. NIH Awards $1.6M to Fund microRNA Biomarker Research in Cancer, Alzheimer's Disease . The Bill & Melinda Gates Foundation today announced $7.7 million in funding for 10 new grants to identify biomarkers for diagnosing tuberculosis (TB) in low-resource settings. NMR metabolomics to demonstrate that divergent environmental signals are transduced into common metabolomic changes that are "sensed" by metabolite-responsive regulators. 

Therapeutic Metabolomics and Disease Diagnostics

Metabolomics is one of the relative newcomers of the omics techniques and is likely the one most closely related to actual real-time disease pathophysiology. The role of metabolism in immunity has been underexplored so far, and yet researchers have made important contributions in describing associations of immune processes and metabolic pathways. Systems immunology aims to study the immune system in the more integrated perspective on how entities and players participate at different system levels to the immune function. Computational immunology is a field of science that encompasses high-throughput genomic and bioinformatics approaches to immunology. The combination of genomic information and simulation of the dynamics of the immune system, in one single tool, can offer new perspectives for a better understanding of the immune system. The Honourable Michelle Rempel, minister of state for western economic diversification, today announced an investment of nearly $3 million toward state-of-the-art metabolomics assessment equipment for the U of A’s new Metabolomics Technology Demonstration Centre, which is set to open in the spring of 2015.

Transcriptomics and Metabolic pathways

Transcriptomics is the study of the transcriptome, the complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell using high-throughput methods, such as microarray analysis . The global transcriptomics market is expected to grow at a CAGR of 13.7% during the forecast period of 2014 to 2019 and is estimated to be worth $3,773.0 million by 2019. The transcriptomics market has blatantly grown in the past few years primarily due to the increasing technological advancements in the field of sequencing technologies in transcriptomics research. Recent advances in metabolomic measurement technologies have been dramatic, extracting biological insight from complex metabolite profiles remains a challenge, an analytical strategy that uses data obtained from high resolution liquid chromatography–mass spectrometry and a bioinformatics toolset for detecting actively changing metabolic pathways upon external perturbation. RNA-Seq is a recently developed approach to transcriptome profiling that uses deep-sequencing technologies. The National Human Genome Research Institute (NHGRI), which is part of the National Institutes of Health (NIH), has participated in two projects that created transcriptome resources for researchers around the world-the Mammalian Gene Collection initiative and the Mouse Transcriptome Project.  

Clinical Metabolomics and Lipidomics

Metabolomics and lipidomics, powerful tools in systems biology, aim to screen small metabolites present in biological samples. Differences in the species or amounts of metabolites can be used to characterize phenotypes and biological responses to perturbations (diseases, genetic modifications, or nutritional and pharmacological treatments). The Thermo Scientific TSQ series mass spectrometer instrument family, combined with high resolution GC or UHPLC, provides unrivaled flexibility and sensitivity for selected ion reaction monitoring (SRM) experiments for quantifying endogenous metabolites and lipids using Thermo Scientific TraceFinder and LC Quan software. Translational Biomarker Discovery Core include identifying, validating and developing pre-clinical biomarkers for establishing the presence of disease, monitoring remission status, determining the efficacy of specific therapeutic protocols, and guiding the selection of specific therapeutic interventions. Linking the results of biomarker studies using protein-protein interaction approaches can assist in systems biology approaches and could lead to hypothesis generation and identification of new drug targets. Science Minister David Willetts has announced £48 million of new investment to help fund research projects aimed at tackling health problems

Plant and Environmental Metabolomics

Metabolomics is the analysis of endogenous and exogenous low molecular mass metabolites within a cell, tissue,or biofluid of an organism in response to an external stressor. The sub-discipline of environmental metabolomics is the application of metabolomic techniques to analyze the interactions of organisms with their environment. Drug metabolism is the process by which the body breaks down and converts medication into active chemical substances. Toxicology is a branch of Medical Science that deals with the effects of chemical compound used in the diagnosis, treatment, or prevention of disease or other abnormal condition on the body. Plant Metabolomics is to study the plant system at the molecular level providing non-biased characterisation of the total metabolite pool (metabolome) of plants under specific conditions. Using Metabolomics, a better understanding of the correlation between genes and the biochemical composition of a plant tissue in response to its environment (phenotype) can be obtained, and this information can be further used to assess gene function (genotype). Four joint U.S. and Japanese research teams have been awarded funding totaling about $12 million (about Yen 960 million) to develop new environmentally-friendly techniques to increase the production of renewable biofuel and reduce pesticide use.

Food and Nutritional Metabolomics

Unlike other ‘omics’ technologies (genomics, proteomics…etc), metabolomics provides biological insight that not only reflects an individual’s unique genetic fingerprint, but also lifestyle, diet and environment. Using metabolomics, researchers can quantitatively analyze non-genetic factors that are involved in postgenomic and posttranscriptional modification. Nutritional metabolomics is rapidly maturing to use small-molecule chemical profiling to support integration of diet and nutrition in complex biosystems research.Nutrigenomics is a branch of nutritional genomics and is the study of the effects of foods and food constituents on gene expression. Foodomics has been recently defined as a new discipline that studies food and nutrition domains through the application of advanced omics technologies in which MS techniques are considered indispensable. Applications of Foodomics include the genomic, transcriptomic, proteomic, and/or metabolomic study of foods for compound profiling, authenticity, and/or biomarker-detection related to food quality or safety; the development of new transgenic foods, food contaminants, and whole toxicity studies; new investigations on food bioactivity, food effects on human health. The University of Michigan Nutrition Obesity Research Center (UM NORC) began in 2010, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The UM NORC is one of 12 U.S. centers designed to inspire and support translational, multi-disciplinary research in obesity and nutrition, across the continuum of basic science to applications in individuals (medicine) and populations (public health)

Enhancing Analytical Approaches in Metabolomics

The rapidly growing area of "metabolomics," in which a large number of metabolites from body fluids, cells or tissue are detected quantitatively, in a single step, promises immense potential for a number of disciplines including early disease diagnosis, therapy monitoring, systems biology, drug discovery and nutritional science. Because of its ability to detect a large number of metabolites in intact biological samples reproducibly and quantitatively, nuclear magnetic resonance (NMR) spectroscopy has emerged as one of the most powerful analytical techniques in metabolomics. Metabolon, Aglient Technologies, Thermo Scientific, Chenomx and Human Metabolome Technologies, Biocrates Life Sciences, and Metanomics are the main leaders in the metabolomics space. They are active in many aspects of this market: diagnostics product development, profiling services, academic collaborations, and even acquisitions. Through the NIH Common Fund's Increasing Metabolomics Research Capacity program External Web Site Policy, the NIH has committed more than $65 million to accelerate the field of metabolomics over the next five years. The goal of this funding program is to advance several core areas, including comprehensive metabolomics resource cores, metabolomics technology development, metabolomics reference standards synthesis, and training and educational activities in metabolomics.

Metabolic Modelling

Metabolism is a vital cellular process, and its malfunction can be a major contributor to many human diseases. Metabolites can serve as a metabolic disease biomarker. An detection of such biomarkers plays a significant role in the study of biochemical reaction and signaling networks. Metabolic profiling, metabolomic and metabonomic studies mainly involve the multicomponent analysis of biological fluids, tissue and cell extracts using NMR spectroscopy and/or mass spectrometry (MS). Metabolic profiling (metabolomics/metabonomics) is the measurement in biological systems of the complement of low-molecular-weight metabolites and their intermediates that reflects the dynamic response to genetic modification and physiological, pathophysiological, and/or developmental stimuli. The current developments in metabolomics and metabolic profiling technologies have led to the discovery of several new metabolic biomarkers. Through the NIH Common Fund's Increasing Metabolomics Research Capacity programExternal Web Site Policy, the NIH has committed more than $65 million to accelerate the field of metabolomics over the next five years. The goal of this funding program is to advance several core areas, including comprehensive metabolomics resource cores, metabolomics technology development, metabolomics reference standards synthesis, and training and educational activities in metabolomics.

Analytical Platforms Employed in Metabolomics

In metabolomics, major efforts are invested in the development of suitable analytical approaches. Metabolomics, the youngest field in the 'omics family, is growing rapidly. Maturing right behind genomics, transcriptomics, and proteomics, metabolomics is the comprehensive analysis of small molecule metabolites. Since most metabolites are generated by enzymatic proteins that result from gene expression, and metabolites give organisms their biochemical characteristics, the metabolome links genotype with phenotype. Metabolomics is still developing, though, as vendors adapt separation and detection instruments to meet its challenges and the research community interprets and integrates the complex data they are acquiring. The recent rapid development of a range of analytical platforms, including GC, HPLC, UPLC, CE coupled to MS and NMR spectroscopy, could enable separation, detection, characterization and quantification of such metabolites and related metabolic pathways. Continued development of these analytical platforms will accelerate widespread use and integration of metabolomics into systems biology. NIH Awards $1.6M to Fund microRNA Biomarker Research in Cancer, Alzheimer's Disease . The Bill & Melinda Gates Foundation today announced $7.7 million in funding for 10 new grants to identify biomarkers for diagnosing tuberculosis (TB) in low-resource settings.

Data Analysis and Integration with Systems Biology

Systems biology is a field within biology aimed at understanding biological processes at the systems level and emerging from dynamic interactions of individual components operating at multiple spatiotemporal scales. It is now an established and fundamental interdisciplinary research field. Systems biology studies biological systems by systematically perturbing them (biologically, genetically, or chemically); monitoring the gene, protein, and informational pathway responses; integrating these data; ultimately, formulating mathematical models that describe the structure of the system and predict its response to individual perturbations. Integrated “omics” approaches have created exciting opportunities for systems biology and other biological researches. Declines in the cost of generating genomic data have made DNA sequencing, RNA-seq, and high-throughput screening an increasingly important part of biomedical research. The National Institute of General Medicine Sciences (NIGMS), an institute of the National Institutes of Health (NIH) supporting basic research and research training, announced earlier this month that it would establish two new divisions — including one focused on biomedical technology, bioinformatics, and computational biology – as part of a reorganization that includes the dissolution of the NIH National Center for Research Resources (NCRR) which has had a history of supporting scientific computing

Applications of Separation Sciences in Metabolomics

Metabolomics, or alternately metabonomics, an emerging field of biochemical research, is a complementary technique to genomics, transcriptomics, and proteomics. Direct quantitative measurements of metabolite expressions in urine, serum, plasma, and tissue are essential for the study of biological processes in normal and disease states. Since the number of metabolites in a biological sample is large separation science plays an important role in metabolomic research. Nuclear magnetic resonance (NMR) spectroscopy is particularly powerful for targeted analysis because it is quantitative, reproducible, and suitable for complex samples such as blood, urine, or tissue extracts with little or no processing. Thermo Fisher, AB SCIEX, and Bruker also offer instruments for imaging MS, also called MALDI imaging. To meet challenges of searchability and data integration, the metabolomics community has several initiatives to establish data repositories. Examples are Metabolights in the United Kingdom, supported by the European COSMOS (COordination of Standards in MetabOlomicS) consortium that is developing metabolomics data standards, and Metabolomics Workbench, which aims to be the database for NIH-funded metabolomics projects. Thermo Fisher collaborates with Fiehn on mzcloud.org, a free community database that includes actual and virtual MS spectra with unknown compounds to be annotated as they are identified.

Summary:

Metabolomics is an emerging field which combines strategies to identify and quantify cellular metabolites using sophisticated analytical technologies with the application of statistical and multi-variant methods for information extraction and data interpretation. Metabolomics is the study of small metabolites. Metabolomics Conference deals with topics like Bioinformatics, proteomics, systems biology, Analytical Techniques like NMR, GC-MS, LC-MS and CE-MS, Lipidomics, Metabolic Modelling, Metabolic profiling, clinical metabolomics, Translational sciences, Mass spectrometry, Metabolomics Syndrome, HPLC and CE based metabolomics and more.  Metabolomics - the new "omics" - is a dynamic and developing field, joining genomics, transcriptomics and proteomics in empowering an integrative frameworks science methodology to drug discovery and development. In spite of the fact that metabolomics is still at an early evolutionary stage it is conjecture that throughout the following decade the biopharma business will apply this innovation all the more generally in drug development and information.

'The Future of Metabolomics' gives fully fledged understanding into the compelling utilization of metabolomics all through drug discovery, preclinical development and clinical trials. The report also highlights the use of metabolomics in maximizing and sustaining revenues post-marketing and in the development of clinical diagnostics.

Importance & Scope:

Metabolomics is now being extensively used in pharmaceutical and biotechnology industries for biomarker and drug discovery; pharmaceutical and biotechnology industries are expected to grow at a high rate in coming years, which is expected to boost the growth of the market.

The National Institutes of Health said that they are to invest $14.3 million for metabolomics research, potentially investing more than $51.4 million over five years, to accelerate an emerging field of biomedical research known as metabolomics. As per National Center for Biotechnology Information. Metabolomics has matured over the past 10 years. Over 300 studies have been completed over the past 5 years. 

Why Osaka, Japan ?

Japan is the second largest Life science market in the world after USA, Occupying about 10% of Market in each of the global drug and Medical devices market. According to Data monitor , the Japanese biotechnology market had a total revenue of $ 43.3 Billion in 2013 . By 2017, the market is expected to grow to $ 53.8 Billion.

The Japanese pharmaceutical market is the world’s second-largest, with 2013 sales estimated at $115 billion. Japan accounts for a little less than 10 percent of the global Pharma market, compared with 38.4 percent for the U.S. and 20.7 percent for Western Europe
 
The Japanese market is a promising region for metabolomics companies, as a high amount of metabolomics research is being conducted in the country.
 
                                            Global Life science Market Share by Country

Why to attend ???

Meet Your Target Market With recent business reports on Metabolomics making news which manifests the tremendous growth in market value for metabolomics technology till 2019. Since metabolomics interrelated with omics sciences like Genomics, precision Medicine, Proteomics, Lipidomics, Fluxomics and Transcriptomics, it would be a great opportunity for companies dealing with Analytical instruments useful in these fields. Also many upcoming students and researchers can benefit themselves by participating world class International workshops, symposia during the conference which will be conducted by experts in the respective fields.

Major Metabolomics Related Associations around the Globe :

Metabolomics Society 
American association for the advancement of science
American association for clinical chemistry  
American association for cancer research
American association of pharmaceutical scientists 
Association for Consumer Research (ACR)
American cancer society 
Bioinformatics society of India 
Nutrigenomics Organization
The British Society for Genetic Medicine
The Genetics Society
Netherlands metabolomics center
The Australian biotechnology association
Human Proteome Organization
Indiana Proteomics Consortium
Proteome Society
European federation of biotechnology
Australasian Proteomics Society
Clinical Genetics Society
 

Major Metabolomics Related  Research Units in Japan :

RIKEN Center for Sustainable Resource Science
Institute for Advanced Biosciences, Keio University
Human Metabolome Technologies
Osaka University
University of Tokyo
Kyoto University
University of Tsukuba
Nagoya University
Hokkaido University
University of Tsukuba
 
Target Audience: 
 
Directors/Managers & Business Delegates,  Director of Laboratories, Universities, Industries, Investigators, Post Doctoral Fellows, Research and Diagnostic Laboratories, Clinical Fellows, Students, Biomedical Research companies.  

Rise in the number of clinical trials, toxicological studies, and health awareness for nutritional products, rapid growth of metabolomics data analysis software and solutions, and use of metabolomics as diagnostics tool for biomarker screening of diseases is expected to propel the growth of this market. 

Glance at Market of Metabolomics:

The market is mainly driven by the increasing research funding for metabolomics from governments and private investors, growing demand for personalized medicine in the U.S. and Europe, and the increasing need for toxicology testing. However, low adoption rates and data complexity inhibits the growth of the metabolomics market to a certain extent. Metabolomics science is used extensively in biomarker discovery and drug assessment. Thus, the rapid growth experienced by pharmaceutical and biotechnology industries is assisting the growth of the metabolomics market.

 
In 2013, North America was the market leader with a share of ~42% of the global market, followed by Europe with a share of ~38%. The presence of a large number of analytical equipment manufacturers has contributed significantly to the North American and European metabolomics market. However, the Asia-Pacific region represents a significant growth opportunity for the metabolomics market during the forecast period of 2014 to 2019. The APAC market is expected to grow at a CAGR of 23% during the forecast period. The growth in this market is driven by the growing pharmaceutical and biotechnology industries.
 
The global metabolomics market was valued at $565 million in 2014 and is expected to grow at a CAGR of 30% from 2014 to 2019. 
 

Statistics which shows growth in importance of Metabolomics :

Metabolomics Market Worth $2,100 Million by 2019 - New Report by  Markets and Markets.

 

Statistics of Industries Associated with Metabolomics :

North America was the market leader with a share of ~42% of the global market, followed by Europe with a share of ~38%. The presence of a large number of analytical equipment manufacturers has contributed significantly to the North American and European metabolomics market. However, the Asia-Pacific region represents a significant growth opportunity for the metabolomics market during the forecast period of 2014 to 2019. The APAC market is expected to grow at a CAGR of 23% during the forecast period. The growth in this market is driven by the growing pharmaceutical and biotechnology industries.

The major players in the metabolomics market include Thermo Fisher Scientific (U.S.), Metabolon, Inc. (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Waters Corporation (U.S.), Agilent Technologies (U.S.), and Bruker Corporation (U.S.). 
 
 

Fund Allotment towards Metabolomics Research :

The National Institutes of Health has provided tens of millions of dollars in new funding to support three new Comprehensive Metabolomics Centers at Mayo Clinic, the University of Kentucky, and the University of Florida. 

These three centers will receive an estimated $9 million to $10 million each over the next five years to create resources and initiate research programs that will ramp up the national metabolomics science capabilities.

NIH provided $14.3 million to fund the launch of three other metabolomics resource centers at the University of Michigan, the Research Triangle Institute, and the University of California, Davis.
 
  • Michigan Regional Comprehensive Metabolomics Resource Core (MRC2) 
  • NIH    West Coast Metabolomics Center at UC Davis
  • Southeast Center for Integrated Metabolomics (SECIM) 
  • Metabolomics Core at Mayo Clinic 
  • Research Center for Stable Isotope Resolved Metabolomics
Funding to UC San Diego for this project is $6 million over five years, part of a total investment by the NIH of $51.4 for the metabolomics project. The awards are supported by the NIH Common Fund.
 
Metabolomic Diagnostics is engaged in a study called IMPROvED, which has received  €6m in European FP7 funding. 
 
Mayo Clinic is one of six new federally-funded Comprehensive Metabolomics centres to support medical research on metabolomics — the study, at the cellular level, of how molecules are metabolized in the body. The award from the National Institutes of Health (NIH) is for $8.8 million over five years.  
 

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date May 16-18, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1
Poster Opportunity Available

Testimonials